Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trialFrançois Raffi, Anton Pozniak, Per O Jansson et al.|The Lancet|2014Cited by 175
A framework for the definition and interpretation of the use of surrogate endpoints in interventional trialsOriana Ciani, Rod S Taylor, Anthony Muchai Manyara et al.|EClinicalMedicine|2023Cited by 60
Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaborationAnthony Muchai Manyara, Oriana Ciani, Philippa Davies et al.|BMJ|2024Cited by 45
Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaborationAnthony Muchai Manyara, Oriana Ciani, Philippa Davies et al.|BMJ|2024Cited by 28
A Framework for the Definition and Interpretation of the Use of Surrogate Endpoints in Interventional Trials’Oriana Ciani, Rod S Taylor, Anthony Muchai Manyara et al.|SSRN Electronic Journal|2023Cited by 0